2017-2018 Archives - Page 3 of 3 - Wockhardt

Financial Results FY 2017 – 18 Q1 (Apr – Jun 2017)

Wockhardt Receives US FDA Approval for Eye Drop for treating Ophthalmic Allergies – 3 July 2017

Shareholding Pattern for the Quarter Ended 30th June 2017

Wockhardt Limited and its Subsidiaries settle with Teva and its Affiliate a commercial litigation in the High Court, London

Wockhardt Limited and its Subsidiaries settle with Teva and its Affiliate a commercial litigation in the High Court, London

Financial Results FY 2017 – 18 Q1 (April – June 2017)

Financial Results FY 2016 – 17 Q4 (Jan – Mar 2017)

WOCKHARDT RECEIVES ACKNOWLEDGEMENT OF ITS BREAKTHROUGH SUPERDRUG ANTIBIOTIC WCK 5222 FOR PHASE III CLINICAL TRIAL FROM US FDA